Outcomes of Geriatric Patients with Hepatocellular Carcinoma

Background: The treatment modalities and outcomes of geriatric patients with hepatocellular carcinoma (HCC) remain controversial. This retrospective observational cohort study compared the outcomes of HCC between geriatric and younger patients. Methods: The medical records of patients with HCC manag...

Full description

Bibliographic Details
Main Authors: Chern-Horng Lee, Tzung-Hai Yen, Sen-Yung Hsieh
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/29/6/346
_version_ 1797488455175897088
author Chern-Horng Lee
Tzung-Hai Yen
Sen-Yung Hsieh
author_facet Chern-Horng Lee
Tzung-Hai Yen
Sen-Yung Hsieh
author_sort Chern-Horng Lee
collection DOAJ
description Background: The treatment modalities and outcomes of geriatric patients with hepatocellular carcinoma (HCC) remain controversial. This retrospective observational cohort study compared the outcomes of HCC between geriatric and younger patients. Methods: The medical records of patients with HCC managed between January 2001 and December 2017 were retrieved from the Chang Gung Memorial Hospital Research Database. Patients were stratified by age into two groups: a geriatric group (65–75 years) and a younger group (<65 years). The two groups were matched through 1:2 propensity score matching (PSM) according to sex, cardiovascular disease, cerebrovascular attack, diabetes mellitus, cirrhosis, hepatitis, and hypertension. Results: Of the 11,033 patients with HCC, 2147 patients aged 65–75 years and 4294 patients aged <65 years were identified after 1:2 PSM. The Kaplan–Meier model revealed that the HCC outcomes in patients older than 65 years were not significantly different after 3 years (<i>p</i> = 0.060). Consistent results were also obtained when the laboratory data associated with HCC incidence were included in the Fine–Gray competing risk model after 1:2 PSM (<i>p</i> = 0.1695). The major risk factors for HCC survival were systemic immune-inflammation index (SII) ≥ 610 × 10<sup>9</sup> cells/L, advanced tumor stage, and model for end-stage liver disease (MELD) score, etc. Conclusion: Age was not an independent factor for mortality in patients with HCC in the first 3 years. Geriatric patients with HCC should be as aggressively managed as younger patients.
first_indexed 2024-03-10T00:02:29Z
format Article
id doaj.art-9400802672c64ea686c75ce12161e2df
institution Directory Open Access Journal
issn 1198-0052
1718-7729
language English
last_indexed 2024-03-10T00:02:29Z
publishDate 2022-06-01
publisher MDPI AG
record_format Article
series Current Oncology
spelling doaj.art-9400802672c64ea686c75ce12161e2df2023-11-23T16:14:21ZengMDPI AGCurrent Oncology1198-00521718-77292022-06-012964332434110.3390/curroncol29060346Outcomes of Geriatric Patients with Hepatocellular CarcinomaChern-Horng Lee0Tzung-Hai Yen1Sen-Yung Hsieh2Division of General Internal Medicine and Geriatrics, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, TaiwanDepartment of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, TaiwanCollege of Medicine, Chang Gung University, Taoyuan 333, TaiwanBackground: The treatment modalities and outcomes of geriatric patients with hepatocellular carcinoma (HCC) remain controversial. This retrospective observational cohort study compared the outcomes of HCC between geriatric and younger patients. Methods: The medical records of patients with HCC managed between January 2001 and December 2017 were retrieved from the Chang Gung Memorial Hospital Research Database. Patients were stratified by age into two groups: a geriatric group (65–75 years) and a younger group (<65 years). The two groups were matched through 1:2 propensity score matching (PSM) according to sex, cardiovascular disease, cerebrovascular attack, diabetes mellitus, cirrhosis, hepatitis, and hypertension. Results: Of the 11,033 patients with HCC, 2147 patients aged 65–75 years and 4294 patients aged <65 years were identified after 1:2 PSM. The Kaplan–Meier model revealed that the HCC outcomes in patients older than 65 years were not significantly different after 3 years (<i>p</i> = 0.060). Consistent results were also obtained when the laboratory data associated with HCC incidence were included in the Fine–Gray competing risk model after 1:2 PSM (<i>p</i> = 0.1695). The major risk factors for HCC survival were systemic immune-inflammation index (SII) ≥ 610 × 10<sup>9</sup> cells/L, advanced tumor stage, and model for end-stage liver disease (MELD) score, etc. Conclusion: Age was not an independent factor for mortality in patients with HCC in the first 3 years. Geriatric patients with HCC should be as aggressively managed as younger patients.https://www.mdpi.com/1718-7729/29/6/346hepatocellular carcinomageriatric patientsmortality
spellingShingle Chern-Horng Lee
Tzung-Hai Yen
Sen-Yung Hsieh
Outcomes of Geriatric Patients with Hepatocellular Carcinoma
Current Oncology
hepatocellular carcinoma
geriatric patients
mortality
title Outcomes of Geriatric Patients with Hepatocellular Carcinoma
title_full Outcomes of Geriatric Patients with Hepatocellular Carcinoma
title_fullStr Outcomes of Geriatric Patients with Hepatocellular Carcinoma
title_full_unstemmed Outcomes of Geriatric Patients with Hepatocellular Carcinoma
title_short Outcomes of Geriatric Patients with Hepatocellular Carcinoma
title_sort outcomes of geriatric patients with hepatocellular carcinoma
topic hepatocellular carcinoma
geriatric patients
mortality
url https://www.mdpi.com/1718-7729/29/6/346
work_keys_str_mv AT chernhornglee outcomesofgeriatricpatientswithhepatocellularcarcinoma
AT tzunghaiyen outcomesofgeriatricpatientswithhepatocellularcarcinoma
AT senyunghsieh outcomesofgeriatricpatientswithhepatocellularcarcinoma